Search

Your search keyword '"Pratz, Keith W."' showing total 559 results
Start Over Author "Pratz, Keith W."
559 results on '"Pratz, Keith W."'

1. Evolving racial/ethnic disparities in AML survival in the novel therapy era

Author

Wang, Xin, Gimotty, Phyllis A., Matthews, Andrew H., Mamtani, Ronac, Luger, Selina M., Hexner, Elizabeth O., Babushok, Daria V., McCurdy, Shannon R., Frey, Noelle V., Bruno, Ximena Jordan, Gill, Saar, Martin, Mary Ellen, Paralkar, Vikram R., Maillard, Ivan, Porter, David L., Loren, Alison W., Perl, Alexander E., Pratz, Keith W., Getz, Kelly D., and Lai, Catherine

Published
2025
Full Text
View/download PDF

2. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine

Author

Pollyea, Daniel A, Pratz, Keith W, Wei, Andrew H, Pullarkat, Vinod, Jonas, Brian A, Recher, Christian, Babu, Sunil, Schuh, Andre C, Dail, Monique, Sun, Yan, Potluri, Jalaja, Chyla, Brenda, and DiNardo, Courtney D

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Rare Diseases, Hematology, Clinical Research, 6.1 Pharmaceuticals, Humans, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Cytogenetic Analysis, Leukemia, Myeloid, Acute, Mutation, Tumor Suppressor Protein p53, Treatment Outcome, Clinical Trials, Phase III as Topic, Clinical Trials, Phase I as Topic, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeTo evaluate efficacy and safety of venetoclax + azacitidine in treatment-naïve patients with acute myeloid leukemia harboring poor-risk cytogenetics and TP53mut or TP53wt.Patients and methodsWe analyzed data from a phase III study (NCT02993523) comparing venetoclax (400 mg orally days 1-28) + azacitidine (75 mg/m2 days 1-7) or placebo + azacitidine, and from a phase Ib study (NCT02203773) of venetoclax + azacitidine. Patients were ineligible for intensive therapy. TP53 status was analyzed centrally; cytogenetic studies were performed locally.ResultsPatients (n = 127) with poor-risk cytogenetics receiving venetoclax + azacitidine (TP53wt = 50; TP53mut = 54) were compared with patients with poor-risk cytogenetics (n = 56) receiving azacitidine alone (TP53wt = 22; TP53mut = 18).For poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine versus azacitidine alone resulted in composite remission rates (CRc) of 70% versus 23%, median duration of remission (DoR) of 18.4 versus 8.5 months, and median overall survival (OS) of 23.4 versus 11.3 months, respectively. Outcomes with venetoclax + azacitidine were comparable with similarly treated patients with intermediate-risk cytogenetics and TP53wt.For poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine versus azacitidine alone resulted in CRc of 41% versus 17%, median DoR of 6.5 versus 6.7 months, and median OS of 5.2 versus 4.9 months, respectively.For poor-risk cytogenetics + TP53mut patients, predominant grade ≥3 adverse events (AE) for venetoclax + azacitidine versus azacitidine were febrile neutropenia (55%/39%), thrombocytopenia (28%/28%), neutropenia (26%/17%), anemia (13%/6%), and pneumonia (28%/33%). AEs were comparable between TP53mut and TP53wt patients.ConclusionsIn poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine improved remission rates but not DoR or OS compared with azacitidine alone. However, in poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine resulted in higher remission rates and longer DoR and OS than azacitidine alone, with outcomes comparable with similarly treated patients with intermediate-risk cytogenetics. Toxicities were similar in TP53mut and TP53wt patients. See related commentary by Green and Zeidner, p. 5235.

Published
2022

4. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Author

Pratz, Keith W, Jonas, Brian A, Pullarkat, Vinod, Recher, Christian, Schuh, Andre C, Thirman, Michael J, Garcia, Jacqueline S, DiNardo, Courtney D, Vorobyev, Vladimir, Fracchiolla, Nicola S, Yeh, Su-Peng, Jang, Jun Ho, Ozcan, Muhit, Yamamoto, Kazuhito, Illes, Arpad, Zhou, Ying, Dail, Monique, Chyla, Brenda, Potluri, Jalaja, and Döhner, Hartmut

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Research, Hematology, Cancer, Rare Diseases, Clinical Trials and Supportive Activities, Good Health and Well Being, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Humans, Leukemia, Myeloid, Acute, Neoplasm, Residual, Prognosis, Remission Induction, Sulfonamides, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThere is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remission (CRc; complete remission + complete remission with incomplete hematologic recovery) and MRD < 10-3 in the VIALE-A trial.MethodsThe patients included in this report were treated with venetoclax and azacitidine. Bone marrow aspirate samples for multiparametric flow cytometry assessments were collected for central analysis at baseline, end of cycle 1, and every three cycles thereafter. MRD-negative response was defined as < 1 residual blast per 1,000 leukocytes (< 10-3 or 0.1%) with an estimated analytic sensitivity of 0.0037%-0.0027%. CRc, duration of remission (DoR), event-free survival (EFS), and overall survival (OS) were assessed. A multivariate Cox regression analysis identified prognostic factors associated with OS.ResultsOne hundred sixty-four of one hundred ninety (86%) patients with CRc were evaluable for MRD. MRD < 10-3 was achieved by 67 of 164 (41%), and 97 of 164 (59%) had MRD ≥ 10-3. The median DoR, EFS, and OS were not reached in patients with CRc and MRD < 10-3, and the 12-month estimates for DoR, EFS, and OS in this group were 81.2%, 83.2%, and 94.0%. Among patients with CRc and MRD ≥ 10-3, the median DoR, EFS, and OS were 9.7, 10.6, and 18.7 months. Multivariate analysis showed that CRc with MRD < 10-3 was a strong predictor of OS (adjusted hazard ratio = 0.285; 95% CI, 0.159 to 0.510; P < .001).ConclusionPatients who achieved CRc and MRD < 10-3 with venetoclax and azacitidine had longer DoR, EFS, and OS, than responding patients with MRD ≥ 10-3.

Published
2022

5. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Author

Pratz, Keith W, Panayiotidis, Panayiotis, Recher, Christian, Wei, Xudong, Jonas, Brian A, Montesinos, Pau, Ivanov, Vladimir, Schuh, Andre C, DiNardo, Courtney D, Novak, Jan, Pejsa, Vlatko, Stevens, Don, Yeh, Su-Peng, Kim, Inho, Turgut, Mehmet, Fracchiolla, Nicola, Yamamoto, Kazuhito, Ofran, Yishai, Wei, Andrew H, Bui, Cat N, Benjamin, Katy, Kamalakar, Rajesh, Potluri, Jalaja, Mendes, Wellington, Devine, Jacob, and Fiedler, Walter

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Cancer, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Cytarabine, Fatigue, Humans, Leukemia, Myeloid, Acute, Quality of Life, Sulfonamides, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.

Published
2022

7. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

Author

Shallis, Rory M, Daver, Naval, Altman, Jessica K, Komrokji, Rami S, Pollyea, Daniel A, Badar, Talha, Bewersdorf, Jan P, Bhatt, Vijaya R, de Botton, Stéphane, de la Fuente Burguera, Adolfo, Carraway, Hetty E, Desai, Pinkal, Dillon, Richard, Duployez, Nicolas, El Chaer, Firas, Fathi, Amir T, Freeman, Sylvie D, Gojo, Ivana, Grunwald, Michael R, Jonas, Brian A, Konopleva, Marina, Lin, Tara L, Mannis, Gabriel N, Mascarenhas, John, Michaelis, Laura C, Mims, Alice S, Montesinos, Pau, Pozdnyakova, Olga, Pratz, Keith W, Schuh, Andre C, Sekeres, Mikkael A, Smith, Catherine C, Stahl, Maximilian, Subklewe, Marion, Uy, Geoffrey L, Voso, Maria Teresa, Walter, Roland B, Wang, Eunice S, Zeidner, Joshua F, Žučenka, Andrius, and Zeidan, Amer M

Published
2023
Full Text
View/download PDF

9. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

Author

Matthews, Andrew H., Perl, Alexander E., Luger, Selina M., Loren, Alison W., Gill, Saar I., Porter, David L., Babushok, Daria V., Maillard, Ivan P., Carroll, Martin P., Frey, Noelle V., Hexner, Elizabeth O., Martin, Mary Ellen, McCurdy, Shannon R., Stadtmauer, Edward A., Paralkar, Vikram R., Bruno, Ximena Jordan, Hwang, Wei-Ting, Margolis, David, and Pratz, Keith W.

Published
2022
Full Text
View/download PDF

10. The impact of post‐remission granulocyte colony‐stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.

Author

DiNardo, Courtney D., Pratz, Keith W., Panayiotidis, Panayiotis, Wei, Xudong, Vorobyev, Vladimir, Illés, Árpád, Kim, Inho, Ivanov, Vladimir, Ku, Grace, Miller, Catherine L., Zhang, Meng, Tatsch, Fernando, Potluri, Jalaja, Schmidt, Xenia, and Récher, Christian

Published
2025
Full Text
View/download PDF

11. Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients

Author

Sung, Anthony D., Koll, Thuy, Gier, Shannon H., Racioppi, Alessandro, White, Griffin, Lew, Meagan, Free, Marcia, Agarwal, Priyal, Bohannon, Lauren M., Johnson, Ernaya J., Selvan, Bharathi, Babushok, Daria V., Frey, Noelle V., Gill, Saar I., Hexner, Elizabeth O., Martin, MaryEllen, Perl, Alexander E., Pratz, Keith W., Luger, Selina M., Chao, Nelson J., Fisher, Alfred L., Stadtmauer, Edward A., Porter, David L., Loren, Alison W., Bhatt, Vijaya R., Gimotty, Phyllis A., and McCurdy, Shannon R.

Published
2024
Full Text
View/download PDF

12. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia

Author

Carraway, Hetty E., Sawalha, Yazeed, Gojo, Ivana, Lee, Min-Jung, Lee, Sunmin, Tomita, Yusuke, Yuno, Akira, Greer, Jackie, Smith, B. Douglas, Pratz, Keith W., Levis, Mark J., Gore, Steven D., Ghosh, Nilanjan, Dezern, Amy, Blackford, Amanda L., Baer, Maria R., Gore, Lia, Piekarz, Richard, Trepel, Jane B., and Karp, Judith E.

Published
2021
Full Text
View/download PDF

14. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Author

Stein, Eytan M., DiNardo, Courtney D., Fathi, Amir T., Mims, Alice S., Pratz, Keith W., Savona, Michael R., Stein, Anthony S., Stone, Richard M., Winer, Eric S., Seet, Christopher S., Döhner, Hartmut, Pollyea, Daniel A., McCloskey, James K., Odenike, Olatoyosi, Löwenberg, Bob, Ossenkoppele, Gert J., Patel, Prapti A., Roshal, Mikhail, Frattini, Mark G., Lersch, Frederik, Franovic, Aleksandra, Nabhan, Salah, Fan, Bin, Choe, Sung, Wang, Hongfang, Wu, Bin, Hua, Lei, Almon, Caroline, Cooper, Michael, Kantarjian, Hagop M., and Tallman, Martin S.

Published
2021
Full Text
View/download PDF

15. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide

Author

Webster, Jonathan A., Luznik, Leo, Tsai, Hua-Ling, Imus, Philip H., DeZern, Amy E., Pratz, Keith W., Levis, Mark J., Gojo, Ivana, Showel, Margaret M., Prince, Gabrielle, Bolaños-Meade, Javier, Gondek, Lukasz P., Ghiaur, Gabriel, Dalton, W. Brian, Jain, Tania, Fuchs, Ephraim J., Gladstone, Douglas E., Gocke, Christian B., Ali, Syed Abbas, Huff, Carol Ann, Borrello, Ivan M., Swinnen, Lode, Wagner-Johnston, Nina, Ambinder, Richard F., Jones, Richard J., and Smith, B. Douglas

Published
2020
Full Text
View/download PDF

16. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Author

Zeidan, Amer M, Boddu, Prajwal C, Patnaik, Mrinal M, Bewersdorf, Jan Philipp, Stahl, Maximilian, Rampal, Raajit K, Shallis, Rory, Steensma, David P, Savona, Michael R, Sekeres, Mikkael A, Roboz, Gail J, DeAngelo, Daniel J, Schuh, Andre C, Padron, Eric, Zeidner, Joshua F, Walter, Roland B, Onida, Francesco, Fathi, Amir, DeZern, Amy, Hobbs, Gabriela, Stein, Eytan M, Vyas, Paresh, Wei, Andrew H, Bowen, David T, Montesinos, Pau, Griffiths, Elizabeth A, Verma, Amit K, Keyzner, Alla, Bar-Natan, Michal, Navada, Shyamala C, Kremyanskaya, Marina, Goldberg, Aaron D, Al-Kali, Aref, Heaney, Mark L, Nazha, Aziz, Salman, Huda, Luger, Selina, Pratz, Keith W, Konig, Heiko, Komrokji, Rami, Deininger, Michael, Cirici, Blanca Xicoy, Bhatt, Vijaya Raj, Silverman, Lewis R, Erba, Harry P, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Wang, Eunice S, Tallman, Martin S, Stone, Richard M, and Mascarenhas, John

Published
2020
Full Text
View/download PDF

17. Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.

Author

Pratz, Keith W.

Subjects
*MYELOPROLIFERATIVE neoplasms, *ACUTE leukemia, *ACUTE myeloid leukemia, *ISOCITRATE dehydrogenase, *LEUKEMIA
Abstract

Outcomes of myeloproliferative neoplasms (MPN)‐associated acute leukaemias are dismal with conventional therapy. Approximately 20% of MPN‐associated acute leukaemias have mutations in isocitrate dehydrogenase (IDH). Olutasidenib, and inhibitor of IDH1, demonstrates important clinical benefits in MPN‐associated leukaemia with IDH1 mutation.Commentary on: Botton et al. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukemia arising from a prior myeloproliferative neoplasm. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19944. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS

Author

Zeidner, Joshua F., Knaus, Hanna A., Zeidan, Amer M., Blackford, Amanda L., Montiel-Esparza, Raul, Hackl, Hubert, Prince, Gabrielle T., Gondek, Lukasz P., Ghiaur, Gabriel, Showel, Margaret M., DeZern, Amy E., Pratz, Keith W., Douglas Smith, B., Levis, Mark J., Gore, Steven, Coombs, Catherine C., Foster, Matthew C., Streicher, Howard, Karp, Judith E., Luznik, Leo, and Gojo, Ivana

Published
2020
Full Text
View/download PDF

21. Post-Transplant Frailty Phenotype Predicts Survival

Author

Hadjis, Ashley D., primary, White, Griffin W., additional, Gill, Saar I., additional, Hossain, Nasheed, additional, Frey, Noelle V., additional, Hexner, Elizabeth O, additional, Bruno, Ximena Jordan, additional, Lai, Catherine E, additional, Matthews, Andrew H., additional, Martin, Mary Ellen, additional, Babushok, Daria V., additional, Perl, Alexander E., additional, Pratz, Keith W., additional, Luger, Selina M., additional, Porter, David L., additional, Loren, Alison W., additional, and McCurdy, Shannon R., additional

Published
2024
Full Text
View/download PDF

22. AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results

Author

Pratz, Keith W., Cherry, Mohamad, Podoltsev, Nikolai A., Altman, Jessica K., Perl, Alexander E., Cooper, Brenda W., Jurcic, Joseph G., Lin, Tara L., Schiller, Gary J., Wu, Ruishan, Hill, Jason E., Gill, Stanley C., James, Angela, Rich, Elizabeth Shima, Hasabou, Nahla, and Levis, Mark J.

Published
2022
Full Text
View/download PDF

23. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Author

DiNardo, Courtney D, Pratz, Keith W, Letai, Anthony, Jonas, Brian A, Wei, Andrew H, Thirman, Michael, Arellano, Martha, Frattini, Mark G, Kantarjian, Hagop, Popovic, Relja, Chyla, Brenda, Xu, Tu, Dunbar, Martin, Agarwal, Suresh K, Humerickhouse, Rod, Mabry, Mack, Potluri, Jalaja, Konopleva, Marina, and Pollyea, Daniel A

Published
2018
Full Text
View/download PDF

24. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML

Author

Pratz, Keith W., primary, Cherry, Mohamad, additional, Altman, Jessica K., additional, Cooper, Brenda W., additional, Podoltsev, Nikolai A., additional, Cruz, Jose Carlos, additional, Lin, Tara L., additional, Schiller, Gary J., additional, Jurcic, Joseph G., additional, Asch, Adam, additional, Wu, Ruishan, additional, Hill, Jason E., additional, Gill, Stanley C., additional, James, Angela J., additional, Rich, Elizabeth Shima, additional, Hasabou, Nahla, additional, Perl, Alexander E., additional, and Levis, Mark J., additional

Published
2023
Full Text
View/download PDF

25. Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia.

Author

Pratz, Keith W., Jonas, Brian A., Pullarkat, Vinod, Thirman, Michael J., Garcia, Jacqueline S., Döhner, Hartmut, Récher, Christian, Fiedler, Walter, Yamamoto, Kazuhito, Wang, Jianxiang, Yoon, Sung‐Soo, Wolach, Ofir, Yeh, Su‐Peng, Leber, Brian, Esteve, Jordi, Mayer, Jiri, Porkka, Kimmo, Illés, Árpád, Lemoli, Roberto M., and Turgut, Mehmet

Published
2024
Full Text
View/download PDF

27. Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia

Author

Matthews, Andrew H., primary, Perl, Alexander E., additional, Luger, Selina M., additional, Gill, Saar I., additional, Lai, Catherine, additional, Porter, David L., additional, Skuli, Sarah, additional, Bruno, Ximena Jordan, additional, Carroll, Martin P., additional, Freyer, Craig W., additional, Carulli, Alison, additional, Babushok, Daria V., additional, Frey, Noelle V., additional, Hexner, Elizabeth O., additional, Martin, Mary Ellen, additional, McCurdy, Shannon R., additional, Stadtmauer, Edward A., additional, Loren, Alison W., additional, Paralkar, Vikram R., additional, Maillard, Ivan P., additional, and Pratz, Keith W., additional

Published
2023
Full Text
View/download PDF

31. Data from Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Author

Pollyea, Daniel A., primary, Pratz, Keith W., primary, Wei, Andrew H., primary, Pullarkat, Vinod, primary, Jonas, Brian A., primary, Recher, Christian, primary, Babu, Sunil, primary, Schuh, Andre C., primary, Dail, Monique, primary, Sun, Yan, primary, Potluri, Jalaja, primary, Chyla, Brenda, primary, and DiNardo, Courtney D., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table from Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

Author

Konopleva, Marina, primary, Thirman, Michael J., primary, Pratz, Keith W., primary, Garcia, Jacqueline S., primary, Recher, Christian, primary, Pullarkat, Vinod, primary, Kantarjian, Hagop M., primary, DiNardo, Courtney D., primary, Dail, Monique, primary, Duan, Yinghui, primary, Chyla, Brenda, primary, Potluri, Jalaja, primary, Miller, Catherine L., primary, and Wei, Andrew H., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data from Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

Author

Konopleva, Marina, primary, Thirman, Michael J., primary, Pratz, Keith W., primary, Garcia, Jacqueline S., primary, Recher, Christian, primary, Pullarkat, Vinod, primary, Kantarjian, Hagop M., primary, DiNardo, Courtney D., primary, Dail, Monique, primary, Duan, Yinghui, primary, Chyla, Brenda, primary, Potluri, Jalaja, primary, Miller, Catherine L., primary, and Wei, Andrew H., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Data from CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia

Author

Ding, Husheng, primary, Vincelette, Nicole D., primary, McGehee, Cordelia D., primary, Kohorst, Mira A., primary, Koh, Brian D., primary, Venkatachalam, Annapoorna, primary, Meng, X. Wei, primary, Schneider, Paula A., primary, Flatten, Karen S., primary, Peterson, Kevin L., primary, Correia, Cristina, primary, Lee, Sun-Hee, primary, Patnaik, Mrinal, primary, Webster, Jonathan A., primary, Ghiaur, Gabriel, primary, Smith, B. Douglas, primary, Karp, Judith E., primary, Pratz, Keith W., primary, Li, Hu, primary, Karnitz, Larry M., primary, and Kaufmann, Scott H., primary

Published
2023
Full Text
View/download PDF

40. Supplemental Data from A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

Author

Gojo, Ivana, primary, Beumer, Jan H., primary, Pratz, Keith W., primary, McDevitt, Michael A., primary, Baer, Maria R., primary, Blackford, Amanda L., primary, Smith, B. Douglas, primary, Gore, Steven D., primary, Carraway, Hetty E., primary, Showel, Margaret M., primary, Levis, Mark J., primary, Dezern, Amy E., primary, Gladstone, Douglas E., primary, Ji, Jiuping Jay, primary, Wang, Lihua, primary, Kinders, Robert J., primary, Pouquet, Marie, primary, Ali-Walbi, Ismail, primary, Rudek, Michelle A., primary, Poh, Weijie, primary, Herman, James G., primary, Karnitz, Larry M., primary, Kaufmann, Scott H., primary, Chen, Alice, primary, and Karp, Judith E., primary

Published
2023
Full Text
View/download PDF

43. Supplemental Table and Figures from Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms

Author

Pratz, Keith W., primary, Koh, Brian D., primary, Patel, Anand G., primary, Flatten, Karen S., primary, Poh, Weijie, primary, Herman, James G., primary, Dilley, Robert, primary, Harrell, Maria I., primary, Smith, B. Douglas, primary, Karp, Judith E., primary, Swisher, Elizabeth M., primary, McDevitt, Michael A., primary, and Kaufmann, Scott H., primary

Published
2023
Full Text
View/download PDF

46. Supplemental Figures and Tables from A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

Author

Pratz, Keith W., primary, Rudek, Michelle A., primary, Gojo, Ivana, primary, Litzow, Mark R., primary, McDevitt, Michael A., primary, Ji, Jiuping, primary, Karnitz, Larry M., primary, Herman, James G., primary, Kinders, Robert J., primary, Smith, B. Douglas, primary, Gore, Steven D., primary, Carraway, Hetty E., primary, Showel, Margaret M., primary, Gladstone, Douglas E., primary, Levis, Mark J., primary, Tsai, Hua-Ling, primary, Rosner, Gary, primary, Chen, Alice, primary, Kaufmann, Scott H., primary, and Karp, Judith E., primary

Published
2023
Full Text
View/download PDF

47. Data from CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia

Author

Ding, Husheng, primary, Vincelette, Nicole D., primary, McGehee, Cordelia D., primary, Kohorst, Mira A., primary, Koh, Brian D., primary, Venkatachalam, Annapoorna, primary, Meng, X. Wei, primary, Schneider, Paula A., primary, Flatten, Karen S., primary, Peterson, Kevin L., primary, Correia, Cristina, primary, Lee, Sun-Hee, primary, Patnaik, Mrinal, primary, Webster, Jonathan A., primary, Ghiaur, Gabriel, primary, Smith, B. Douglas, primary, Karp, Judith E., primary, Pratz, Keith W., primary, Li, Hu, primary, Karnitz, Larry M., primary, and Kaufmann, Scott H., primary

Published
2023
Full Text
View/download PDF

48. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Author

McCurdy, Shannon R., Kanakry, Jennifer A., Showel, Margaret M., Tsai, Hua-Ling, Bolaños-Meade, Javier, Rosner, Gary L., Kanakry, Christopher G., Perica, Karlo, Symons, Heather J., Brodsky, Robert A., Gladstone, Douglas E., Huff, Carol Ann, Pratz, Keith W., Prince, Gabrielle T., Dezern, Amy E., Gojo, Ivana, Matsui, William H., Borrello, Ivan, McDevitt, Michael A., Swinnen, Lode J., Smith, B. Douglas, Levis, Mark J., Ambinder, Richard F., Luznik, Leo, Jones, Richard J., Fuchs, Ephraim J., and Kasamon, Yvette L.

Published
2015
Full Text
View/download PDF

49. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies

Author

Connor, Matthew P., primary, Loren, Alison W., additional, Hexner, Elizabeth O., additional, Martin, Mary Ellen, additional, Gill, Saar I., additional, Luger, Selina M., additional, Mangan, James K., additional, Perl, Alexander E., additional, McCurdy, Shannon R., additional, Pratz, Keith W., additional, Timlin, Colleen, additional, Freyer, Craig W., additional, Carulli, Alison, additional, Catania, Christopher, additional, Smith, Jacqueline, additional, Hollander, Lauren, additional, Zebrowski, Alexis M., additional, Stadtmauer, Edward A., additional, Porter, David L., additional, and Frey, Noelle V., additional

Published
2023
Full Text
View/download PDF

50. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Author

Kanakry, Christopher G., Tsai, Hua-Ling, Bolaños-Meade, Javier, Smith, B. Douglas, Gojo, Ivana, Kanakry, Jennifer A., Kasamon, Yvette L., Gladstone, Douglas E., Matsui, William, Borrello, Ivan, Huff, Carol Ann, Swinnen, Lode J., Powell, Jonathan D., Pratz, Keith W., DeZern, Amy E., Showel, Margaret M., McDevitt, Michael A., Brodsky, Robert A., Levis, Mark J., Ambinder, Richard F., Fuchs, Ephraim J., Rosner, Gary L., Jones, Richard J., and Luznik, Leo

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results